In a stunning display of growth, Miami-based AI startup OpenEvidence, often dubbed the 'ChatGPT for doctors,' has doubled its valuation to $12 billion in a recent Series D funding round.
This remarkable achievement comes just months after its last funding, showcasing the skyrocketing demand for AI-driven solutions in healthcare.
The Rise of AI in Healthcare
Founded three years ago, OpenEvidence has rapidly positioned itself as a leader in medical AI by providing clinical decision support tools trained on prestigious medical journals like JAMA and the New England Journal of Medicine.
The platform, which offers free access to verified medical professionals through an ad-supported model, has reportedly been adopted by 40% of U.S. physicians, handling millions of consultations monthly.
Details of the Series D Funding
The latest $250 million round, led by Thrive Capital and DST, with backing from industry giants like Nvidia and Google Ventures, underscores investor confidence in OpenEvidence’s vision.
This funding follows a $200 million raise in October 2025 at a $6 billion valuation, marking one of the fastest valuation climbs in healthcare AI history.
Impact on the Medical Field
By enabling doctors to quickly access trusted medical information, OpenEvidence is transforming patient care, reducing diagnostic errors, and saving critical time in high-pressure environments.
The startup’s tools are seen as a game-changer, especially in an era where healthcare systems are under strain, addressing gaps in access to up-to-date clinical evidence.
Looking to the Future
With this influx of capital, OpenEvidence plans to expand its reach globally, targeting markets with significant physician shortages and enhancing its AI capabilities.
Analysts predict that the company could play a pivotal role in shaping the future of telemedicine and personalized medicine as AI continues to integrate into healthcare workflows.
However, challenges remain, including ensuring data privacy and addressing ethical concerns surrounding AI in medical decision-making.
As OpenEvidence continues to grow, its journey from a $1 billion valuation in early 2025 to $12 billion today serves as a testament to the transformative power of AI innovation in solving real-world problems.
Alfred Lee
